Company intelligence / Profile preview

Coach

Salt Lake City, Utah, United States

Ownership: Private
Development stage: Other

Overview

Coach Therapeutics is a biotechnology company focused on developing innovative gene therapies for the treatment of heart failure. The company's lead program utilizes a gene therapy approach to deliver the cardiac bridging integrator 1 (cBIN1) gene, which acts as a master regulator of heart cell architecture. By restoring the structural integrity of cardiomyocytes, the therapy aims to improve cardiac function and survival in patients with failing hearts. Coach Therapeutics is currently advancing its platform through pre-clinical studies with the goal of entering human clinical trials to address the significant unmet need in chronic heart failure management.

Therapeutic areas: Cardiovascular
Modalities: Gene therapy
Industry: Biotech

Beyond the preview

Go deeper on Coach.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coach.

Explore the full profile